Phenethyl isothiocyanate potentiates anti-tumour effect of doxorubicin through Akt-dependent pathway. 2015

Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.

The present study aims to investigate the in vivo and in vitro anti-tumour properties of phenethyl isothiocyanate (PEITC) alone and in combination with doxorubicin (Dox). The anti-tumour activity was evaluated in vitro by MTT assay using cultured human breast cancer cell line (MCF-7) and human hepatoma cell line (HepG-2) cell lines. In vivo, Ehrlich solid tumour model was used. Tumour volume, weight and antioxidant parameters were determined. Immunohistochemistry analysis for active (cleaved) caspase-3 was also performed. We tested the effect of PEITC treatment on pAkt/Akt ratio, NF-κB p65 DNA binding activity and caspase-9 enzyme activity in both MCF-7 and HepG-2 cell lines. Effect of PEITC treatment on cell migration was assessed by wound healing assay. PEITC and/or Dox treatment significantly inhibited solid tumour volume and tumour weight when compared with control mice. PEITC treatment significantly reduced oxidative stress caused by Dox treatment as indicated by significant increase in total antioxidant capacity and decrease in malondialdehyde level. Microscopic examination of tumour tissues showed a significant increase in active (cleaved) caspase-3 expression in PEITC and/or Dox treated groups. PEITC showed a dose-dependent inhibition of MCF-7 and HepG-2 cellular viability. PEITC inhibited Akt and NF-κB activation and increased caspase-9 activity in a dose-dependent manner. PEITC treatment effectively inhibited both MCF-7 and HepG-2 cell migration. We can conclude that PEITC acts via multiple molecular targets to elicit anti-carcinogenic activity. PEITC/Dox combination therapy might be a potential novel strategy, which may benefit patients with breast and liver cancers.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
April 2018, Molecular carcinogenesis,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
July 2019, Bioscience, biotechnology, and biochemistry,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
April 2013, Life sciences,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
June 2009, Central European journal of public health,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
May 2012, International journal of cardiology,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
October 2020, Journal of ethnopharmacology,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
June 2018, Naunyn-Schmiedeberg's archives of pharmacology,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
January 2022, Oxidative medicine and cellular longevity,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
November 2013, Naunyn-Schmiedeberg's archives of pharmacology,
Nada H Eisa, and Nehal M ElSherbiny, and Abdelhadi M Shebl, and Laila A Eissa, and Mamdouh M El-Shishtawy
December 2014, Biochimica et biophysica acta,
Copied contents to your clipboard!